- Home
- QNST vs VTYX Comparison
QNST vs VTYX Comparison
Compare QNST & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNST | VTYX |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.3M | 713.6M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QNST | VTYX |
|---|---|---|
| Price | $14.74 | $8.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $26.40 | $14.60 |
| AVG Volume (30 Days) | 557.1K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,100,345,000.00 | N/A |
| Revenue This Year | $11.73 | N/A |
| Revenue Next Year | $9.82 | N/A |
| P/E Ratio | $81.67 | ★ N/A |
| Revenue Growth | ★ 43.12 | N/A |
| 52 Week Low | $12.98 | $0.78 |
| 52 Week High | $25.50 | $10.55 |
Technical Indicators
Market Signals| Indicator | QNST | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 47.80 |
| Support Level | $14.45 | $8.39 |
| Resistance Level | $14.79 | $9.13 |
| Average True Range (ATR) | 0.46 | 0.58 |
| MACD | 0.09 | -0.24 |
| Stochastic Oscillator | 57.48 | 22.39 |
Price Performance
Historical ComparisonAbout QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.